targeted therapy

BOTHELL, WASHINGTON, April 29, 2026 Immunome has announced the submission of a New Drug Application (NDA) to the U.S....

WATERTOWN, MASSACHUSETTS, April 28, 2026 Kestrel Therapeutics Inc. has announced a major clinical milestone with the first patient dosed...

SHANGHAI, April 23, 2026 Mabwell has announced the initiation of a Phase III clinical trial for its proprietary Nectin-4-targeting...

Paris, France – April 22, 2026 In a major breakthrough for pediatric oncology, Ipsen has announced that the European...

South San Francisco, California, USA, April 21, 2026 In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has...

Cambridge, Massachusetts, USA, April 21, 2026 In a major advancement for targeted cancer therapy, Nuvalent, Inc. has announced the...

SAN DIEGO, Calif., April 21, 2026 Cardiff Oncology, Inc. announced it will present updated Phase 2 data for its...

REDWOOD CITY, Calif., April 19, 2026 A major breakthrough in targeted oncology therapy has emerged as Revolution Medicines unveiled...

SAN DIEGO and PARIS, April 17, 2026 Kura Oncology, Inc. reported encouraging clinical data from its ongoing FIT-001 trial,...

CAMBRIDGE, Mass., April 17, 2026 Nuvalent, Inc. has reported compelling clinical and preclinical data for its investigational drug zidesamtinib,...